4D Molecular Therapeutics, Inc.
FDMT
$3.04
-$0.09-2.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.89% | -99.82% | -99.92% | 785.20% | 826.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.89% | -99.82% | -99.92% | 785.20% | 826.69% |
| Cost of Revenue | 50.30% | 45.54% | 34.23% | 28.22% | 23.15% |
| Gross Profit | -87.72% | -84.98% | -76.02% | -7.67% | -1.27% |
| SG&A Expenses | 26.85% | 27.61% | 28.49% | 21.94% | 18.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.86% | 40.64% | 32.67% | 26.47% | 21.90% |
| Operating Income | -68.18% | -66.43% | -60.46% | -11.72% | -6.29% |
| Income Before Tax | -68.75% | -59.53% | -49.56% | 1.32% | 4.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.75% | -59.53% | -49.56% | 1.32% | 4.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.75% | -59.53% | -49.56% | 1.32% | 4.81% |
| EBIT | -68.18% | -66.43% | -60.46% | -11.72% | -6.29% |
| EBITDA | -70.57% | -68.58% | -62.39% | -11.37% | -5.26% |
| EPS Basic | -30.87% | -12.36% | -3.57% | 30.42% | 28.25% |
| Normalized Basic EPS | -30.87% | -12.36% | -3.58% | 30.42% | 28.25% |
| EPS Diluted | -30.87% | -12.36% | -3.57% | 30.42% | 28.28% |
| Normalized Diluted EPS | -30.87% | -12.36% | -3.58% | 30.42% | 28.25% |
| Average Basic Shares Outstanding | 28.65% | 38.14% | 39.21% | 39.54% | 32.95% |
| Average Diluted Shares Outstanding | 28.65% | 38.14% | 39.21% | 39.54% | 32.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |